Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Felzartamab in Kidney Transplant Recipients With AMR or MVI
NCT07444489Phase 3Enrolling by invitation
- Sponsor
- Biogen
- Start
- Apr 2026
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of felzartamab in antibody mediated rejection (AMR), microvascular inflammation (MVI), sponsored by Biogen. Started Apr 2026; status: enrolling by invitation.
02
Drugs
felzartamab
03
Conditions
antibody mediated rejection (AMR)microvascular inflammation (MVI)
Beyond the preview
Go deeper on NCT07444489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444489.